Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06657768 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
A Phase 1 study of Healthy and Alzheimer Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 9
- Study locations
NCT06657768: Recruiting Phase 1 study of Healthy and Alzheimer Disease, sponsored by Eli Lilly and Company.
NCT06657768 is a Phase 1 study of Healthy and Alzheimer Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 128 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06657768, a Phase 1 study of Healthy and Alzheimer Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 9
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.
Primary Outcome
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4006895
Study Locations (9)
Florida
- K2 Medical Research - The Villages - Lady Lake
- K2 Medical Research - Maitland
Georgia
- Atlanta Center of Medical Research - Atlanta
- CenExel iResearch, LLC (CenExel iRA) - Decatur
Other
- The University of Tokyo Hospital - Bunkyō City
- National Center for Geriatrics and Gerontology - Ōbu
California
- Collaborative Neuroscience Network - CNS - Los Alamitos
New Jersey
- CenExel-HRI - Marlton
North Carolina
- Duke Early Phase Research Unit - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT06657768 shows while recruiting
NCT06657768 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06657768 lists 9 locations in 6 states (Florida, Georgia, Other).
Frequently Asked Questions
What is clinical trial NCT06657768 about?
NCT06657768 is a clinical study titled "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)". The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). ...
What is the current status of trial NCT06657768?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2024-10-29. Estimated completion is 2027-07.
What conditions does trial NCT06657768 study?
This clinical trial studies the following conditions: Healthy, Alzheimer Disease.
What interventions are being tested in trial NCT06657768?
The interventions under investigation include: Placebo (DRUG), LY4006895 (DRUG).
Who is sponsoring clinical trial NCT06657768?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06657768 being conducted?
This trial has 9 study locations across California, Florida, Georgia, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06657768's enrollment target sits among peer trials
128 174th of 1090 higher than 917 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI